Hologic has announced the completion of its acquisition of Gynesonics, a privately held medical device company focused on minimally invasive solutions for women’s health. The transaction, valued at approximately $350 million, brings Gynesonics’ Sonata System under Hologic’s portfolio of women’s health solutions.
The Sonata System provides diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The technology combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.
“We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata System, which complements and expands our range of minimally invasive solutions for heavy periods and fibroids,” said Brandon Schnittker, President of Surgical Solutions at Hologic. “As global champions for women’s health, we are dedicated to empowering surgeons with diverse, cutting-edge treatment options as we strive to transform women’s lives for the better.”
Skip Baldino, President and Chief Executive Officer of Gynesonics, commented on the acquisition: “As we embark on this new phase with Hologic, we are excited to see the continued success of the Sonata System, which has already made a difference in the lives of thousands of women. Hologic’s commitment to women’s health and their leadership in innovation make them a perfect fit for our organization.”
The acquisition expands Hologic’s portfolio in women’s health, where the company has established itself as a global leader in developing medical technologies for detection, diagnosis, and treatment.
